AbCellera Biologics Inc.

NasdaqGS ABCL

AbCellera Biologics Inc. EBIT Margin for the year ending December 31, 2023: -586.59%

AbCellera Biologics Inc. EBIT Margin is -586.59% for the year ending December 31, 2023, a -1,290.91% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

AbCellera Biologics Inc. EBIT Margin for the year ending December 31, 2022 was 49.26%, a -17.63% change year over year.
AbCellera Biologics Inc. EBIT Margin for the year ending December 31, 2021 was 59.80%, a -15.16% change year over year.
AbCellera Biologics Inc. EBIT Margin for the year ending December 31, 2020 was 70.49%, a 508.92% change year over year.
AbCellera Biologics Inc. EBIT Margin for the year ending December 31, 2019 was -17.24%, a -102.03% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqGS: ABCL

AbCellera Biologics Inc.

CEO	Dr. Carl L.G. Hansen Ph.D.
IPO Date	Dec. 11, 2020
Location	Canada
Headquarters	2215 Yukon Street
Employees	586
Sector	Health Care
Industries Biotechnology Artificial Intelligence (AI) Pharmaceuticals

Description

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Key trends

Past 5 years